ArticleBMC cancer2026
Genome-wide DNA methylation profiling reveals body mass Index-dependent epigenetic signatures associated with lung cancer susceptibility.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to investigate the association between body mass index (BMI)-related DNA methylation alterations and lung cancer risk.
methodsWe conducted a case–control study involving 250 patients with lung cancer and 250 healthy controls. The Illumina 450 K methylation array was used to assess DNA methylation levels in peripheral blood samples. Multivariate logistic regression analysis was performed. Gene Ontology and pathway enrichment analyses were conducted to explore the biological functions of related genes.
resultsAmong the 15,000 CpG sites that passed quality control, 1,200 sites showed significant correlation with BMI. We identified 15 CpG sites as being significantly associated with lung cancer risk, with the most significant being hypermethylation of PARK2 (cg00012345; odds ratio [OR] = 2.5, 95% confidence interval [CI]: 1.7–3.6) and hypomethylation of TP53 (cg04236487; OR = 1.8, 95%CI: 1.3–2.5). Moreover, BMI stratification analysis revealed stronger associations between DNA methylation and lung cancer risk in overweight and obese groups, with PARK2 methylation showing increased risk in the overweight group (OR = 2.2, 95%CI: 1.6–3.0) and ADIPOQ methylation in the obese group (OR = 1.8, 95%CI: 1.3–2.5). Pathway analysis identified significant enrichment in p53 signalling, MAPK signalling, apoptosis and immune response pathways (p < 0.05). The associations of PARK2 and TP53 methylation with lung cancer risk were confirmed in two independent validation cohorts with similar effect sizes.
conclusionsThis study provides the first systematic evidence for the key role of BMI-related DNA methylation alterations in lung cancer development, particularly in overweight and obese populations. Methylation changes in genes may serve as potential biomarkers for lung cancer risk prediction, offering new strategies for early screening and prevention of lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.